Albumedix is committed to creating and developing superior biotherapeutics built on its proprietary recombinant albumin-based products and technologies for increased patient care, including Veltis® for optimized drug delivery and Recombumin® for improved drug formulation. It is a global company and a fully-owned subsidiary of Novozymes.
The establishment of Albumedix will not have any operational impact on current collaborations and should only strengthen our ability to serving our customer’s needs.
For more information, please find the recent press release, or visit the new Albumedix website.
Novozymes’ enzyme solutions for the pharmaceutical industry remain a part of the Novozymes business and will continue to be further developed. For more information please contact our Pharma Enzyme Team.